United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $167,432,054.58. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
United Therapeutics Price Performance
NASDAQ UTHR opened at $518.68 on Wednesday. The business has a fifty day moving average price of $541.40 and a two-hundred day moving average price of $533.37. United Therapeutics Corporation has a fifty-two week low of $291.22 and a fifty-two week high of $609.35. The stock has a market capitalization of $22.02 billion, a PE ratio of 19.15, a PEG ratio of 1.73 and a beta of 0.59.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the business posted $6.63 EPS. The company's revenue for the quarter was down 1.6% on a year-over-year basis. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.65 earnings per share for the current year.
Institutional Trading of United Therapeutics
Several institutional investors have recently modified their holdings of the business. Arjuna Capital increased its holdings in United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC lifted its holdings in United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after buying an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC lifted its holdings in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after buying an additional 24 shares during the period. Meeder Advisory Services Inc. lifted its holdings in United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock worth $392,000 after buying an additional 26 shares during the period. Finally, Independent Advisor Alliance grew its position in shares of United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock valued at $406,000 after buying an additional 27 shares during the last quarter. Institutional investors own 94.08% of the company's stock.
Analysts Set New Price Targets
A number of research firms have recently commented on UTHR. Weiss Ratings cut shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday. Wells Fargo & Company upgraded shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $701.00 to $704.00 and gave the company an "outperform" rating in a research note on Tuesday, July 7th. TD Cowen restated a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $648.33.
Check Out Our Latest Stock Analysis on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
